Praxis Precision Medicines
Tracked across 4 events · 26 articles · First seen Apr 02, 2026 · Last active Jul 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Praxis Precision Medicines announced that the United States — Food and Drug Administration accepted its New Drug Application for ulixacaltamide HCl, moving the company closer to commercial launch of a new therapy for essential tremor.
Apr 14, 2026 · 6 articles
Business
Impact: Praxis Precision Medicines, Inc. granted restricted stock unit awards to new non-executive employees under its 2024 Inducement Plan, which is a positive for the company's ability to attract and retain talent.
Apr 02, 2026 · 8 articles
Domestic
Impact: Praxis Precision Medicines>>> is identified as a major revolution in the healthcare sector, with scientists urged to collaborate on inventing solutions that transform medical science.
Jun 10, 2026 · 6 articles
Business
Impact: Dr. Daniel Baker provided critical guidance during the merger of Praxis Precision Medicines and Argus retinal prosthesis, which led to the formation of Vivani Medical.
Jun 26, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Praxis Precision Medicines live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard